No peptide has been shown to cause cancer in a person. No study has been designed to find out either.
The concern is real, and it is mostly not about the peptide. It is about IGF-1, the hormone these compounds exist to raise. IGF-1 has a substantial cancer literature behind it.
That literature points three ways at once. People with naturally higher IGF-1 have modestly higher rates of several cancers. People with pathologically high levels have clearly higher rates of one. And people given growth hormone to correct a deficiency show no increase at all.
The position nobody has studied is the one peptide users occupy: starting with normal IGF-1 and pushing it above normal on purpose.
Does raising IGF-1 increase cancer risk?
Sermorelin, ipamorelin, CJC-1295, tesamorelin and MK-677 all work by prompting your body to release more growth hormone. Growth hormone acts largely through IGF-1, and raising IGF-1 is how you know these are working. Our guide to the growth hormone peptides covers that relationship.
IGF-1 also does what its name says. It is a growth factor: it tells cells to divide and it discourages them from dying on schedule. Cancer cells do exactly those two things, which is where the worry comes from. It remains a mechanism and not a finding. What turns it into something checkable is that IGF-1 has been measured in hundreds of thousands of people.
What the IGF-1 cancer studies found
Large prospective studies have followed people for years and compared cancer rates against IGF-1 measured before any diagnosis.
In UK Biobank, higher IGF-1 was associated with increased risk of colorectal cancer at a hazard ratio of 1.08, breast cancer at 1.11, and prostate cancer at 1.08, along with thyroid cancer and possibly melanoma and multiple myeloma. It was associated with lower risk of liver and ovarian cancer.[^1]
A pooled analysis of individual data from nineteen studies, covering more than 10,000 prostate cancer cases, confirmed a moderate positive association. Men in the highest fifth of IGF-1 had around 29% higher risk than those in the lowest.[^2]
The hazard ratios are modest. A 1.08 hazard ratio is an 8% relative increase, which on a common cancer is a real effect at population scale and a small one for any individual.
And there is evidence they are causal, not merely correlated. Mendelian randomisation studies, which use inherited genetic variation as a natural experiment, suggest the associations for these cancers may be causal.[^1] That is a stronger claim than an observed association and it is why this concern deserves taking seriously.
Is growth hormone therapy linked to cancer?
Growth hormone has been prescribed to adults with growth hormone deficiency for decades, and those patients have been tracked in large registries specifically because of this question.
KIMS covered 15,809 treated patients. Overall cancer incidence matched the general population, at a standardised incidence ratio of 0.92. There was no increased risk of prostate or colon cancer, and breast cancer incidence came in significantly lower than expected.[^3]
The HypoCCS study found no evidence of increased primary cancer in treated adults against the general population. It also found no association when treated patients were compared with untreated ones.[^3]
A meta-analysis of more than 11,000 patients found growth hormone replacement associated with reduced cancer risk in this population, at a relative risk of 0.69.[^4]
So the direct test of raising growth hormone in adults, run over years in tens of thousands of people, does not show the harm the epidemiology predicts.
What acromegaly shows at the top of the range
Acromegaly is the condition where the body produces far too much growth hormone continuously, usually from a pituitary tumour. That makes it the natural experiment at the top of the range.
People with acromegaly have an established increased risk of colorectal cancer.[^5]
Across the whole range the picture bends. Correcting a deficiency to normal appears safe or protective. Sitting naturally at the top of the normal range carries a modest increase. Sitting far above normal for years carries a clear increase for at least one cancer.
Where peptide users sit on that range
Read those three findings together and the shape becomes clear. Risk seems to track with where your IGF-1 sits relative to normal, and for how long.
Growth hormone replacement moves a deficient person up to normal, and that population is the one with reassuring data.
A secretagogue moves a person with normal IGF-1 above normal, deliberately, for as long as they keep taking it. That is a different position from anyone in the registries, and closer in direction, though nowhere near in magnitude, to the acromegaly end.
Nobody has studied it. No cohort exists of healthy adults who raised their IGF-1 pharmacologically for years, because that population is new, unmonitored, and buying online.
Understanding that gap explains why both the reassuring answer and the alarming answer are overstated. The reassuring data comes from a different population. The alarming data comes from a different mechanism.
Does how long you take it matter?
Two variables drive this, and so far only one of them has come up.
Every number on this page describes a duration. The epidemiology measures lifetime exposure to a person's own IGF-1 level, set at birth and running for decades. The KIMS registry averaged around five years of treatment. Acromegaly usually runs for years before diagnosis.
Against that, someone running eight weeks and someone running three years are in genuinely different positions, and neither has been studied.
None of that produces a safe duration, because no such figure exists for any compound here. It does mean duration belongs in the decision alongside the compound, and that the schedules run continuously, without breaks and without an end date, sit furthest from anything anyone has measured.
How age changes the arithmetic
Cancer risk is overwhelmingly driven by age. The same relative increase lands very differently depending on where your baseline sits.
A hazard ratio of 1.08 applied to a 35-year-old's low absolute risk is a very small number. Applied to a 65-year-old's substantially higher baseline, the same ratio produces a larger absolute change.
Most people taking growth hormone compounds are between 30 and 50, and in absolute terms the epidemiology reads most reassuringly for them. The other end, where the calculation shifts and the trial evidence points at a different problem entirely, is a guide of its own.
Is BPC-157 or TB-500 linked to cancer?
Two more concerns get raised, and both are mechanistic and neither is measured.
BPC-157 is proposed to work by promoting the growth of new blood vessels. Tumours need new blood vessels to grow beyond a small size, which is why angiogenesis inhibitors are a class of cancer drug.
TB-500 and thymosin beta-4 act on cell migration. Metastasis is cell migration.
Neither has been shown to cause or accelerate cancer in anything. Neither has been studied for it either, and our guide to the pair covers how thin the evidence base is generally. The honest description is a plausible mechanism with no data on either side, which puts them below the IGF-1 question and not above it.
Does semaglutide cause thyroid cancer?
Most people asking about peptides and cancer are asking this one, because it is printed on a label.
Semaglutide and tirzepatide carry a boxed warning about thyroid C-cell tumours. That warning came from rodents, where these drugs caused thyroid tumours at high doses over long exposures, and rodent thyroid tissue responds differently from human tissue.
The human evidence has moved. A 2024 systematic review covered ten randomised trials and 14,550 participants, and found thyroid cancer incidence under 1% in semaglutide-treated patients. A 2026 analysis pooled trial, post-marketing and real-world data, and concluded there is no association between semaglutide or liraglutide exposure and thyroid cancer.
That same analysis reported a second finding. Thyroid cancer appeared more often in the treatment arms than in the comparator arms, with hazard ratios of 1.70 and 1.83, and it cited a separate meta-analysis of 87,465 people finding a statistically significant increase at an odds ratio of 1.55. The event numbers are small enough that none of it settles the question.
So the warning remains on the label. The human evidence does not support the level of fear it created, and it does not support calling the question closed either, with the full citations in our safety guide.
This is a different question from the rest of the subject. It concerns a specific tissue and a specific drug class, and it has nothing to do with IGF-1.
What this means if you are deciding
If you have an active cancer
Every source agrees on this one. Growth hormone is contraindicated in active malignancy, and the same caution applies across this whole category.
If you have had cancer
This is a conversation with your oncologist and not a website. The registry data on survivors is mixed, with some analyses showing increased risk of second cancers in younger patients treated after childhood cancer.[^3]
If you have a strong family history
Particularly of prostate, breast or colorectal cancer, the epidemiology above is about exactly those three. That does not make a compound unsafe for you, and it makes the question worth raising with a doctor who knows your history.
If none of that applies
The absolute risk implied by the epidemiology is small, the duration matters, and nobody has measured the thing you would be doing.
Do not skip screening
Whatever you take, the age-appropriate cancer screening for your situation is the intervention with actual evidence behind it.
What to actually do about it
Nothing on this page is compound-specific, which is the point.
Know your family history. The three cancers the IGF-1 epidemiology concerns are colorectal, breast and prostate, and all three have a strong familial component. Somebody who knows their history has better information than any risk estimate on this page.
Do the screening you would do anyway. Age-appropriate cancer screening is the intervention with actual evidence behind it, and it is the same recommendation whether you take anything or not. Taking a compound is not a reason to screen more, and it is certainly not a reason to skip it.
Know the general warning signs. Unexplained weight loss, a lump that persists, blood where there should not be any, a change in bowel habit lasting weeks, a mole that changes. Those apply regardless of what you take, and our melanotan guide covers the last of them in detail because that compound has a specific reason to care.
Tell your doctor what you take. Not because it changes their screening advice, but because it changes how they interpret an unexplained result. Our guide on drug testing covers why IGF-1 in particular can surface unexpectedly.
What would change this picture
A cohort study following people using growth hormone secretagogues over years, with IGF-1 measured and cancer incidence tracked. Nothing like it exists.
Longer follow-up in the growth hormone registries, since cancer takes decades and the mean follow-up in KIMS was around five years.
Any trial of a research peptide long enough and large enough to detect a signal. For cancer that means thousands of people over many years, and nobody has attempted it for any compound covered here.
Where this stops being useful
Your individual risk. Age, family history, smoking, weight and screening history all matter more than anything on this page.
Whether a specific compound is safe for you, which is a clinical question resting on things a website does not know.
How much IGF-1 elevation matters, or for how long. The epidemiology measures natural variation within a normal range. Nobody has characterised what a pharmacological elevation does over months or years.
Common questions
Do peptides cause cancer?
No peptide has been shown to cause cancer in a person, and no study has been designed to check. The concern is mechanistic and it centres on IGF-1, which has a real cancer literature behind it.
Does raising IGF-1 increase cancer risk?
Higher natural IGF-1 is associated with modestly higher risk of colorectal, breast and prostate cancer, and genetic analyses suggest those associations may be causal.[^1] Growth hormone treatment in deficient adults, which raises IGF-1 to normal, shows no increased risk.[^3] The position in between has not been studied.
Is BPC-157 linked to cancer?
Not by any study. The concern is that it is proposed to promote new blood vessel growth, which is something tumours require. That is a mechanism with no evidence on either side.
Can I take peptides if I have had cancer?
That is a question for your oncologist. Growth hormone is contraindicated in active malignancy, and registry data in survivors is mixed.
Do GLP-1 drugs cause thyroid cancer?
The evidence there is more developed than for anything else on this page, and our safety guide covers what the reviews found, including where they disagree.
Should I get my IGF-1 tested?
If you are taking a growth hormone compound, knowing your number beats not knowing it, and it is an ordinary test any doctor can order. What no one can tell you is how to read that number against your cancer risk, because nobody has established the translation.
Does cycling reduce the risk?
Nobody knows. No study has compared continuous against intermittent use for any outcome, let alone this one. The cycling schedules circulating have no published basis.
Does semaglutide cause thyroid cancer?
The boxed warning came from rodent studies. A 2024 review of ten randomised trials found thyroid cancer incidence under 1%, and a 2026 pooled analysis found no association, while also reporting hazard ratios of 1.70 and 1.83 trending the other way on small event numbers. The warning remains on the label and the question remains open.
Does it matter how long I take it?
Almost certainly, and nobody has measured it. Every figure on this page describes a duration: lifetime exposure in the epidemiology, around five years in the registries, years in acromegaly. Eight weeks and three years are different situations and neither has been studied.
Does my age change the risk?
Considerably, because cancer risk is driven overwhelmingly by age. The same relative increase produces a much smaller absolute change at 35 than at 65.
What should I actually watch for?
The same things anyone should: unexplained weight loss, a persistent lump, unexpected bleeding, a bowel habit change lasting weeks, a mole that changes. None of that is peptide-specific, and age-appropriate screening for your situation does more good than any of it.
Is this concern overblown?
Both answers you will read are overstated. The reassuring one comes from a population being corrected to normal. The alarming one comes from a mechanism nobody has tested in the people asking.
Sources
[^1]: Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank. Cancer Research 2020;80(18):4014. Peer-reviewed prospective cohort analysis, abstract and results read at source. Higher serum IGF-I was associated with increased risk of colorectal cancer, hazard ratio 1.08, breast cancer in women, 1.11, and prostate cancer, 1.08, plus thyroid cancer, malignant melanoma and multiple myeloma. Inverse associations were found for liver and ovarian cancer. The paper notes that Mendelian randomisation analyses suggest the positive associations with colorectal, breast and prostate cancer may be causal.
[^2]: A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Research 2016;76(8):2288. Peer-reviewed pooled analysis, abstract read at source. Individual participant data from 17 prospective and 2 cross-sectional studies, up to 10,554 prostate cancer cases and 13,618 controls. Confirms moderate positive associations between prediagnostic IGF-I and prostate cancer risk. Excluding one study, men with high IGF-I had 29% higher risk than those with low concentrations. The analyses include over 98% of published worldwide prospective data on IGFs and prostate cancer.
[^3]: Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15,809 GH-Treated Patients. Journal of Clinical Endocrinology and Metabolism 2022;107(7):1906. Peer-reviewed registry analysis, abstract and results read at source. KIMS cohort. Overall all-site de novo cancer standardised incidence ratio 0.92, 95% CI 0.83 to 1.01, after mean follow-up of 5.3 years. No increased risk for prostate cancer, 1.21, 95% CI 0.97 to 1.50, colon cancer, 0.66, 95% CI 0.41 to 1.01, or breast cancer, 0.56, 95% CI 0.40 to 0.77. Records that HypoCCS found no evidence of increased primary cancer in hypopituitary adults compared with the general population, and no association when treated patients were compared with untreated. Separate KIMS analysis found increased second malignancy risk in childhood-onset cancer survivors but not adult-onset, which is the basis for the cancer survivor caution in the body text.
[^4]: Growth hormone replacement therapy reduces risk of cancer in adults with growth hormone deficiency: a meta-analysis. Oncotarget, 2016. Peer-reviewed meta-analysis, abstract read at source. 11,191 subjects. Growth hormone replacement associated with decreased cancer risk in adults with growth hormone deficiency, relative risk 0.69, 95% CI 0.59 to 0.82, low heterogeneity. Cited here as a counterweight; note that the journal has faced criticism over editorial standards and the finding should be weighted alongside the KIMS and HypoCCS registry data rather than on its own.
[^5]: Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World Journal of Gastroenterology 2008;14(22):3484. Peer-reviewed meta-analysis, abstract read at source. Pooled nine studies. Colorectal cancer risk elevated in acromegaly, odds ratio 2.6, 95% CI 1.7 to 4.0, and colorectal adenomas elevated at odds ratio 2.0, 95% CI 1.4 to 2.7. This is the page's evidence for the high end of the range.